Bluebird Bio Inc. (NASDAQ:BLUE) received a $85.00 price objective from stock analysts at Maxim Group in a report released on Thursday. The firm currently has a a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 15.96% from the stock’s previous close.
BLUE has been the subject of several other reports. Cowen and Company restated an “outperform” rating on shares of Bluebird Bio in a report on Friday, September 9th. Wedbush restated an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a report on Thursday, September 8th. BTIG Research restated a “buy” rating and set a $72.00 price target on shares of Bluebird Bio in a report on Sunday, September 11th. Vetr cut shares of Bluebird Bio from a “strong-buy” rating to a “sell” rating and set a $44.44 price target for the company. in a report on Wednesday, June 8th. Finally, Jefferies Group restated a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a report on Friday, July 8th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Bluebird Bio has a consensus rating of “Buy” and a consensus price target of $89.17.
Bluebird Bio (NASDAQ:BLUE) traded down 2.10% during midday trading on Thursday, reaching $71.76. 480,229 shares of the company were exchanged. The firm’s 50-day moving average is $57.41 and its 200-day moving average is $48.29. The firm’s market cap is $2.67 billion. Bluebird Bio has a one year low of $35.37 and a one year high of $113.26.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The business’s revenue for the quarter was down 68.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.57) earnings per share. On average, equities analysts expect that Bluebird Bio will post ($6.16) EPS for the current fiscal year.
In related news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $477,848. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sullivan sold 2,807 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total transaction of $126,427.28. Following the transaction, the insider now directly owns 4,656 shares in the company, valued at approximately $209,706.24. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the company. State Street Corp raised its position in shares of Bluebird Bio by 25.9% in the first quarter. State Street Corp now owns 1,201,936 shares of the company’s stock worth $51,088,000 after buying an additional 247,254 shares during the period. OMERS ADMINISTRATION Corp raised its position in shares of Bluebird Bio by 1.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 6,000 shares of the company’s stock worth $255,000 after buying an additional 100 shares during the period. RTW Investments LLC bought a new position in shares of Bluebird Bio during the first quarter worth about $9,621,000. JPMorgan Chase & Co. raised its position in shares of Bluebird Bio by 7.0% in the first quarter. JPMorgan Chase & Co. now owns 59,623 shares of the company’s stock worth $2,535,000 after buying an additional 3,906 shares during the period. Finally, Clarius Group LLC bought a new position in shares of Bluebird Bio during the first quarter worth about $410,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.